What happened in this episode?
Peter Attia interviews Jim Otvos, a physical chemist who developed NMR-based blood analysis that underpins advanced lipoprotein testing (LDL-P/HDL-P). Otvos recounts how a disputed 1980s New England Journal of Medicine cancer claim led his lab to identify reproducible NMR signals from lipoprotein particles, enabling rapid particle quantification and later subclass sizing. He argues that apparent risk from “small, dense” LDL is largely explained by higher LDL particle numbers at a given LDL-cholesterol level, warning against the common “large, fluffy LDL is safe” interpretation.
The discussion then centres on discordance between LDL-C and LDL-P, links to insulin resistance, and how NMR-derived composite scores such as LPIR and the Diabetes Risk Index may help identify metabolic risk earlier than glucose-based criteria. Otvos also describes “glyc”, an NMR-derived inflammation marker tied to glycosylated acute-phase proteins, which he says is more stable than CRP.
A major focus is MVX (metabolic vulnerability index), a composite score (including small HDL-P, glyc, citrate and branched-chain amino acids) that Otvos says strongly predicts all-cause mortality across cohorts, including claims of prediction in a young-adult cohort followed for decades. Finally, he gives an insider account of Liposcience’s acquisition by LabCorp, saying it halted plans to deploy FDA-cleared Vanta NMR analysers broadly and raising concerns about the ageing analyser fleet and long-term continuity of NMR testing.
